Ocrevus (ocrelizumab) vs Fleqsuvy (baclofen)

Ocrevus (ocrelizumab) is a monoclonal antibody medication specifically designed to treat certain forms of multiple sclerosis (MS), including relapsing-remitting MS and primary progressive MS, by targeting CD20-positive B cells that are thought to play a role in the disease's pathogenesis. Fleqsuvy (baclofen) is a muscle relaxer and an antispastic agent used to relieve muscle symptoms, such as spasm, pain, and stiffness, typically associated with conditions like spasticity in multiple sclerosis, spinal cord injuries, or other neurological disorders. When deciding between Ocrevus and Fleqsuvy, it is essential to consider the primary goal of treatment: Ocrevus is used to modify the course of MS, while Fleqsuvy is aimed at managing specific symptoms related to muscle spasticity and not the underlying disease itself.

Difference between Ocrevus and Fleqsuvy

Metric	Ocrevus (ocrelizumab)	Fleqsuvy (baclofen)
Generic name	Ocrelizumab	Baclofen
Indications	Primary progressive multiple sclerosis (PPMS), relapsing forms of multiple sclerosis (RMS)	Spasticity of skeletal muscles, multiple sclerosis, spinal cord injuries, other spinal cord diseases
Mechanism of action	CD20-directed cytolytic antibody	GABA-B receptor agonist
Brand names	Ocrevus	Fleqsuvy, Lioresal
Administrative route	Intravenous infusion	Oral, intrathecal
Side effects	Infusion reactions, infections, skin cancer, depression, pain	Drowsiness, dizziness, weakness, fatigue, headache, insomnia, nausea
Contraindications	Active hepatitis B infection, history of life-threatening infusion reaction to ocrelizumab	Hypersensitivity to baclofen, epilepsy, Parkinson's disease, renal impairment
Drug class	CD20-directed monoclonal antibody	Antispastic agent
Manufacturer	Genentech (Roche)	Supernus Pharmaceuticals

Efficacy

Ocrevus (Ocrelizumab) Efficacy in Treating Multiple Sclerosis

Ocrevus (ocrelizumab) is a monoclonal antibody designed to target CD20-positive B cells, which are believed to play a key role in the pathogenesis of multiple sclerosis (MS). In clinical trials, Ocrevus has shown efficacy in reducing the rate of relapses in people with relapsing forms of MS (RMS), including relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). For RRMS, Ocrevus has been demonstrated to reduce the annual relapse rate significantly compared to interferon beta-1a, a commonly used MS therapy. Additionally, Ocrevus has been associated with a reduction in the progression of disability and a decrease in the number of new or enlarging brain lesions as seen on MRI scans.

For patients with PPMS, Ocrevus is the first and only therapy approved to treat this form of MS. It has been shown to slow the progression of disability in PPMS, which is a significant advancement given the limited treatment options for this type of MS. The efficacy of Ocrevus in PPMS was measured by the time required for the disease to progress, and it was found to be beneficial in delaying disease progression.

Fleqsuvy (Baclofen) Efficacy in Treating Multiple Sclerosis

Fleqsuvy (baclofen) is a medication that is primarily used to treat spasticity, a common symptom in MS patients. It is not a disease-modifying drug like Ocrevus but rather a symptomatic treatment that helps to relieve certain symptoms associated with MS. Baclofen acts on the central nervous system to produce its muscle relaxant effects. While it does not alter the course of MS, it can significantly improve the quality of life for patients by reducing muscle stiffness and spasms, which can be painful and debilitating.

The efficacy of baclofen in treating spasticity in MS has been well-documented through various studies. It is considered one of the first-line treatments for managing spasticity symptoms. Patients taking baclofen have reported improvements in muscle tone and a reduction in the frequency and severity of muscle spasms. The medication's effectiveness can vary among individuals, and it is typically titrated to the optimal dose to balance the therapeutic effect with any potential side effects.

Regulatory Agency Approvals

Ocrevus

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Fleqsuvy

Food and Drug Administration (FDA), USA

Access Ocrevus or Fleqsuvy today

If Ocrevus or Fleqsuvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Ocrevus

Buy Fleqsuvy

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: